exRNAdisease

General Information

Database ID:

exR0087832

RNA Name:

hsa-miR-185-5p

RNA Type:

miRNA

Chromosome:

chr22

Starnd:

Coordinate:

Start Site(bp):

20033153

End Site(bp):

20033174

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
TFAP2A	chr6	10393186	10419659	-
SSH2	chr17	29625938	29930276	-
ZBTB4	chr17	7459366	7484263	-
CTSA	chr20	45890144	45898820	+
TSPAN14	chr10	80454166	80533124	+
ACVR1B	chr12	51951699	51997078	+
GRB2	chr17	75318076	75405709	-
RAB5A	chr3	19947097	19985175	+
RAB40C	chr16	589357	629272	+
VPS37B	chr12	122865330	122896127	-
SLC29A1	chr6	44219553	44234142	+
NDRG1	chr8	133237171	133302022	-
HDLBP	chr2	241227264	241317061	-
RSU1	chr10	16590611	16817463	-
HADHA	chr2	26190635	26244672	-
VPS4A	chr16	69311350	69326939	+
IGF2BP1	chr17	48997385	49056145	+
NF1	chr17	31094927	31382116	+
SMAD3	chr15	67063763	67195169	+
ORAI1	chr12	121626550	121642677	+
ADGRG1	chr16	57610652	57665580	+
TNRC6B	chr22	40044817	40335808	+
ZMIZ1	chr10	79068966	79316528	+
GOLGA1	chr9	124878275	124948492	-
ZBTB38	chr3	141324213	141449792	+
SLC29A2	chr11	66362521	66372214	-
GATAD2B	chr1	153789030	153923360	-
GBA2	chr9	35736866	35749228	-
OTUD4	chr4	145110838	145180589	-
FAM234A	chr16	234521	272183	+

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0001658	chr6	157357968	157406039	+
hsa_circ_0000711	chr16	68155889	68160513	+
hsa_circ_0001168	chr20	47691321	47707559	+
hsa_circ_0001146	chr20	34241449	34246936	-
hsa_circ_0001164	chr20	45891031	45923523	-

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC007952.4	chr17	19112000	19112636	-
AC008040.1	chr3	169939353	169966734	-
AC021092.1	chr19	44103007	44113183	-
LINC01278	chrX	63222993	63561095	-
MALAT1	chr11	65497688	65506516	+
MIR137HG	chr1	97933474	98049863	-
MIR663AHG	chr20	26167817	26251546	-
NEAT1	chr11	65422774	65445540	+
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.